Schöffel G, Zimmermann R, Harenberg J, Mörl H
Thromb Res. 1982;25(1-2):11-21. doi: 10.1016/0049-3848(82)90210-9.
The efficacy and the safety of a new urokinase dosage regimen (loading dose 250,000 IU, initial maintenance dosage 2,000 IU/kg/h in combination with heparin) was studied in ten cases of deep vein thrombosis with regard to the changes of the blood coagulation and fibrinolytic enzyme system. The coagulation analyses demonstrated a pronounced activation of the fibrinolytic system with a statistically significant (p less than 0.05) shortening of the euglobulin clot lysis time and increase of the FDP. The fibrinogen concentration ranged from 50-100 mg/dl already after 12-36 hours. Plasminogen was reduced by 63%, alpha 2-macroglobulin by 32% and factor VIII:C by 42% (p less than 0.05 each). The decrease of fibrinogen (Clauss method) related well to the method of Ratnoff and Menzie, the reduction of plasminogen and the shortening of the euglobulin clot lysis time. According to our data, a sufficient plasma fibrinogenolytic activity may permit on its own an assessment of an adequate therapy with urokinase and the requirements of dose adjustment. The dosage regimen applied here proved effective and readily controllable. Relevant side reactions were not observed.
研究了一种新的尿激酶给药方案(负荷剂量250,000国际单位,初始维持剂量2,000国际单位/千克/小时并联合肝素)对10例深静脉血栓形成患者凝血和纤溶酶系统变化的疗效及安全性。凝血分析显示纤溶系统有明显激活,优球蛋白凝块溶解时间在统计学上显著缩短(p<0.05),FDP增加。12至36小时后纤维蛋白原浓度已降至50 - 100毫克/分升。纤溶酶原降低63%,α2 -巨球蛋白降低32%,因子VIII:C降低42%(各p<0.05)。纤维蛋白原(Clauss法)的降低与Ratnoff和Menzie法、纤溶酶原的降低以及优球蛋白凝块溶解时间的缩短密切相关。根据我们的数据,足够的血浆纤维蛋白溶解活性本身可能有助于评估尿激酶治疗的充分性及剂量调整需求。此处应用的给药方案证明有效且易于控制。未观察到相关不良反应。